Amgen wins a key approval for platelet therapy

Amgen got some much-needed good news yesterday after an FDA panel endorsed the approval of Nplate, its drug for a rare blood disorder. The expert group backed Nplate, saying that its benefits in treating chronic immune thrombocytopenia purpura, or ITP, outweighed the risks posed by the injectable drug. The market potential for Nplate, though, is limited. One analyst estimated that Nplate is likely to earn only about $117 million a year. Still, that's a plus sign after a turbulent period that's seen plenty of minuses for Amgen. Nplate is an engineered version of a protein that spurs platelet production.

- here's the release
- check out the AP report

Related Articles:
Experts to weigh in on Amgen's Nplate. Report
Amgen platelet therapy hits endpoint in Phase III. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.